For every Amazon, there are a dozen Pet.Coms, eToys and Webvans. For every Bill Gates and Steve Jobs, there are thousands of ...

Weight loss clinics, telehealth companies, physicians, and pharmacies that have been prescribing or dispensing compounded GLP ...

With Eli Lilly’s Mounjaro entering India, the weight-loss drug race is on. But with steep prices and generics on the way, how ...

The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...

Eli Lilly launches Mounjaro in India, targeting the $150B weight-loss market. The GLP-1 drug offers diabetes control & major ...

First, Novo Nordisk is expanding its program to sell Wegovy GLP-1 weight loss drugs at discounted prices. Second, Novo is ...

The licensing pact adds a second so-called "triple agonist" to the Danish drugmaker's portfolio as competition with Lilly and other contenders heats up.

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and ...

Zerodha’s Nithin Kamath sparks debate on Ozempic, Mounjaro & their game-changing impact on obesity, addiction & industries. Is India ready for this shift?

We recently published a list of 13 Best Healthcare Dividend Stocks to Invest in. In this article, we are going to take a look ...

Mounjaro, a newly launched weight-loss and diabetes drug, is now available in India. Developed by Eli Lilly, it promises more effectiveness than Ozempic and comes at a lower cost. Experts believe it ...

Novo Nordisk agreed to pay up to $2 billion for the rights to a developmental weight-loss and obesity drug from Chinese pharmaceutical company the United Bio-Technology (Hengqin) Co., as it looks to ...